Cap

Zacks Small Cap Research – QNRX: More Positive Data Supporting Efficacy of QRX003 for NS; Campaign to Raise Awareness of the Disease – Go Health Pro

by
Zacks Small Cap Research – QNRX: More Positive Data Supporting Efficacy of QRX003 for NS; Campaign to Raise Awareness of the Disease – Go Health Pro

By M. Marin NASDAQ:QNRX READ THE FULL QNRX RESEARCH REPORT Positive interim clinical data Quoin Pharmaceuticals (NASDAQ:QNRX) is a clinical stage, specialty pharmaceutical company that focuses on developing treatments for rare and orphan diseases, initially in the dermatology space. The company is advancing clinical studies to evaluate lead asset QRX003 for the treatment of Netherton … Read more

Zacks Small Cap Research – EDSA: Raises $15 Million to Advance EB06… – Go Health Pro

by
Zacks Small Cap Research – EDSA: Raises Million to Advance EB06… – Go Health Pro

By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Advancing EB06 for Treating Vitiligo Edesa Biotech, Inc. (NASDAQ:EDSA) is planning for a Phase 2 study of its anti-CXCL10 monoclonal antibody for the treatment of moderate-to-severe non-segmental vitiligo patients. Vitiligo is a disease that causes areas of the skin to lose color, … Read more

Zacks Small Cap Research – OMH: Backdrop of Industry Fundamentals, Positive Implications – Go Health Pro

by
Zacks Small Cap Research – OMH: Backdrop of Industry Fundamentals, Positive Implications – Go Health Pro

By M. Marin NASDAQ:OMH READ THE FULL OMH RESEARCH REPORT HDB sales volume up in 2024 … Ohmyhome Ltd (NASDAQ:OMH), a Singapore-based technology company that operates an online real estate platform, has experienced substantial momentum, reflecting the ongoing strength of the domestic property market and its growth initiatives. For example, resale prices and volume sales … Read more

Zacks Small Cap Research – MGRM: Monogram’s Potential for 2025 Commercialization of its mBôs Total Knee Arthroplasty Robotic System Supports Price Target of $6.00. – Go Health Pro

by

By Thomas Kerr, CFA NASDAQ:MGRM READ THE FULL MGRM RESEARCH REPORT Regulatory Update On February 26, 2025, Monogram (NASDAQ:MGRM) announced an update regarding its 510(k) premarket filing submission to the FDA for the company’s mBôs TKA System. The company stated it had completed all supplemental testing and submitted its formal response to the Additional Information … Read more

x